Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WM7M
|
|||
| Drug Name |
Anti-CD19 CAR-T cell therapy
|
|||
| Indication | B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1 | [1] | |
| Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1] | ||
| Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [2] | ||
| Company |
Kite PharmaSanta Monica, CA National Cancer Institute Bethesda, MD
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.